Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ipsen
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Adult men, ≥18 years old, with recently diagnosed locally advanced or metastatic prostate cancer scheduled to receive androgen deprivation therapy as monotherapy or as concomitant and adjuvant therapy in association with radiation therapy, with a 1 or 3 month GnRH analogue triptorelin formulation
Expected survival \> 12 months.
Patients having provided written informed consent.
Patients mentally fit for completing a questionnaire.
You may not be if
Treatment with any investigational drug within the last 3 months before study entry or planning to participate in a study.
Patients who already have been treated with a GnRH analogue within the last year.
Patients with hypersensitivity to GnRH, GnRH analogue, triptorelin or its excipients.
Patients with a contraindication according to SmPC.
Clareo Health | Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer
